Physician profile
Shuchee Madhusudan
NPI 1841477346
$2,553.35
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,827 · 2020: $221 · 2021: $172 · 2022: $218 · 2024: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $549.96 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $304.67 | 2019 | |
| Abbvie INC. | $230.77 | 2019-2020 | |
| Amgen INC. | $170.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.13 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $155.14 | 2019-2020 | |
| Glaxosmithkline, LLC. | $148.72 | 2019-2024 | Arexvy |
| Corcept Therapeutics | $143.65 | 2019 | |
| Shire North American Group INC | $121.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $81.74 | 2019-2021 | |
| Novo Nordisk INC | $60.06 | 2019-2020 | |
| Ibsa Pharma INC. | $56.34 | 2019-2020 | |
| Mylan Specialty L.P. | $48.61 | 2019-2020 | |
| Lilly USA, LLC | $42.80 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $36.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.65 | 2020 | |
| Insulet Corporation | $23.52 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.55 | 2019 | |
| Seqirus USA INC | $17.16 | 2019 | |
| Electromed, INC. | $16.09 | 2019 | |
| Braintree Laboratories, INC. | $15.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuchee Madhusudan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.